Results 1 to 10 of about 1,019,401 (119)

Clinical Evaluation of Drug–Drug Interactions With Aficamten [PDF]

Clinical and Translational Science
Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
doaj   +2 more sources

Navigating Drug–Drug Interactions in Clinical Drug Development: A Tutorial [PDF]

Clinical and Translational Science
This tutorial provides essential guidelines and insights, in addition to regulatory guidance, for the evaluation of drug–drug interactions (DDIs), with a focus on the tools and timing of assessment critical for effective management of inclusion/exclusion
Jesmin Lohy Das, Antoinette (Toni) Ajavon‐Hartmann, Virginia (Ginny) D. Schmith   +2 more
doaj   +2 more sources

Tutorial Drug–Drug Interactions [PDF]

Clinical and Translational Science
Edward M. Sellers
doaj   +2 more sources

PRELIMINARY INVESTIGATION ON THE PRODUCTION OF SURFACE ACTIVE COMPOUNDS WITH ANTIMICROBIAL AND EMULSIFYING PROPERTIES BY BACILLUS CLAUSII AND LACTOBACILLUS RHAMNOSUS PROBIOTIC STRAINS [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University, 2021
Surface active compounds (SACs) of bacterial origin are amphiphilic heteropolymers that may alter the interaction of gas-liquid, solid-liquid, and immiscible liquids surfaces, decrease the surface and interfacial tensions of liquids, and form stable ...
Marcus Dias-Souza, Renan dos Santos, Tiago Fonseca   +2 more
doaj   +1 more source

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions

Pharmaceutics, 2021
Due to the growing use of herbal supplementation—ease of taking herbal supplements with therapeutics drugs (i [...]
Min-Koo Choi, Im-Sook Song
doaj   +1 more source

Predicting drug-target interactions using drug-drug interactions. [PDF]

PLoS ONE, 2013
Computational methods for predicting drug-target interactions have become important in drug research because they can help to reduce the time, cost, and failure rates for developing new drugs.
Shinhyuk Kim, Daeyong Jin, Hyunju Lee
doaj   +1 more source

Crystal structure correlations with the intrinsic thermodynamics of human carbonic anhydrase inhibitor binding [PDF]

PeerJ, 2018
The structure-thermodynamics correlation analysis was performed for a series of fluorine- and chlorine-substituted benzenesulfonamide inhibitors binding to several human carbonic anhydrase (CA) isoforms.
Alexey Smirnov, Asta Zubrienė, Elena Manakova, Saulius Gražulis, Daumantas Matulis   +4 more
doaj   +2 more sources

Drug-drug interactions of tacrolimus [PDF]

Hospital Pharmacology, 2015
Introduction: Tacrolimus, potent immunosupressive drug, has large inter- and intraindividual pharmacokinetic variability. The aim: The aim of this current topic is to describe the importance of tacrolimus drug-drug interactions.
Rančić Nemanja K., Vavić Neven N., Kovačević Aleksandra M., Mikov Momir M., Dragojević-Simić Viktorija M.   +4 more
doaj   +1 more source

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions

Pharmaceuticals, 2021
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event.
Martina Hahn, Sibylle C. Roll
doaj   +1 more source

Prevalence and Clinical Significance of Drug–Drug and Drug–Dietary Supplement Interactions among Patients Admitted for Cardiothoracic Surgery in Greece

Pharmaceutics, 2021
Background: Drug interactions represent a major issue in clinical settings, especially for critically ill patients such as those with cardiovascular disease (CVD) who require cardiothoracic surgery (CTS) and receive a high number of different medications.
Marios Spanakis, Maria Melissourgaki, George Lazopoulos, Athina E. Patelarou, Evridiki Patelarou   +4 more
doaj   +1 more source